• Users Online: 322
  • Print this page
  • Email this page


 
 Table of Contents  
EDITORIAL
Year : 2020  |  Volume : 11  |  Issue : 3  |  Page : 125

Management of coronavirus disease-2019 (COVID-19) in patients with diabetes


1 Department of Molecular Genetics, Madras Diabetes Research Foundation, Chennai, Tamil Nadu, India
2 Department of Diabetology, Madras Diabetes Research Foundation & Dr. Mohan’s Diabetes Specialities Centre, Chennai, Tamil Nadu, India

Date of Submission25-Jul-2020
Date of Acceptance25-Jul-2020
Date of Web Publication1-Sep-2020

Correspondence Address:
Dr. Dhanasekaran Bodhini
Madras Diabetes Research Foundation, No 4, Conran Smith Road, Gopalapuram, Chennai, Tamil Nadu.
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/JOD.JOD_67_20

Rights and Permissions

How to cite this article:
Bodhini D, Mohan V. Management of coronavirus disease-2019 (COVID-19) in patients with diabetes. J Diabetol 2020;11:125

How to cite this URL:
Bodhini D, Mohan V. Management of coronavirus disease-2019 (COVID-19) in patients with diabetes. J Diabetol [serial online] 2020 [cited 2020 Nov 26];11:125. Available from: https://www.journalofdiabetology.org/text.asp?2020/11/3/125/294053



In continuation of the previous issue of Journal of Diabetology (JOD) with a special section on coronavirus disease-2019 (COVID-19), this issue of JOD also has a series of four articles pertaining to management of diabetes in the context of COVID-19. The first article by Dayal and Yadav[1] discusses the possible risks to children and adolescents with diabetes during the current pandemic and the special considerations in management of those affected with COVID-19. In the second article, Singh[2] has elegantly reviewed the use of dipeptidyl peptidase 4 (DPP-4) inhibitors in patients with diabetes and COVID-19. Though insulin remains a mainstay in the treatment of patients with COVID-19, this article reassures us regarding continuing DPP-4 inhibitors in mild-to-moderate cases highlighting few real-world data available till date and its potential beneficial/neutral effects in patients with COVID-19. The third article by Bhowmick et al.[3] from Bangladesh Diabetic Association (BADAS) provides an evidence-based guidance for the prevention and care of people with diabetes during the COVID-19 pandemic. It also has a section on management of COVID-19 in people with diabetes outlining the diet plan, exercise plan, medication plan for glycemic control and care to be taken after discharge from hospital. The fourth article is by Unnikrishnan et al.[4] and presents three cases illustrating how telemedicine has helped management of newly diagnosed gestational diabetes mellitus. They propose telemedicine as a useful tool for managing gestational diabetes in selected situations where the patients are asymptomatic and hemodynamically, as well as clinically, stable.

Apart from this special section on COVID-19, our regular articles on clinical studies related to the management and prevention of diabetes and its complications have been included in this issue. One of the significant articles is the review article by Kumar et al.[5] which focuses on the current global and national guidelines for optimum use of insulin in type 2 diabetes. The authors discuss about the initiation of insulin at the time of diagnosis and also after failure of oral drugs. They have also discussed about the advantages of insulin analogs and the role of the recently available insulin co-formulations.

We have received many articles on COVID-19 and we plan to continue the special section on COVID-19 in the subsequent issues as well. With the surge in the number of manuscripts received and the exponential growth in the readership of the journal, we propose to increase the number of issues from next year to four issues per year from the current three issues per year. Hopefully, the number of issues will further increase in the years to come. We seek your continuous support for the growth of JOD.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.



 
  References Top

1.
Dayal D, Yadav A COVID-19: considerations for children and adolescents with diabetes. J Diabetol 2020;11:126-30.  Back to cited text no. 1
    
2.
Singh A DPP4 inhibitors in type 2 diabetes and Covid 19. A potential repurpose agent to useful treatment option. J Diabetol 2020;11:131-6.  Back to cited text no. 2
  [Full text]  
3.
Bhowmik B, Ahmed T, Afsana F, Qureshi NK, Siddiquee T, Pathan F, et al. Guide on diabetes and COVID-19 for healthcare professionals in Bangladesh. J Diabetol 2020;11:137-43.  Back to cited text no. 3
  [Full text]  
4.
Simon MR, Sarkar N, Kumaran S, Chittake A, Purandare V, Unnikrishnan AG . Telemedicine for the initial management of newly diagnosed gestational diabetes in the pandemic period: a report of three case studies. J Diabetol 2020;11:144-7.  Back to cited text no. 4
  [Full text]  
5.
Kumar A, Sharma SK, Gupta A, Dasgupta A, Asirvatham AJ, Talwalkar PG, et al. Indian reality of managing type 2 diabetes: an expert review of global and national guidelines for optimum insulin use. J Diabetol 2020;11:148-57.  Back to cited text no. 5
  [Full text]  




 

Top
 
 
  Search
 
Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
Access Statistics
Email Alert *
Add to My List *
* Registration required (free)

 
  In this article
References

 Article Access Statistics
    Viewed910    
    Printed52    
    Emailed0    
    PDF Downloaded148    
    Comments [Add]    

Recommend this journal


[TAG2]
[TAG3]
[TAG4]